(Q34498182)

2 August 2017

1 reference

title

Receptor tyrosine kinases as targets for anticancer drugs (English)

1 reference

2 August 2017

Esther Zwick

1

1 reference

2 August 2017

Johannes Bange

series ordinal

2

1 reference

2 August 2017

Axel Ullrich

series ordinal

3

1 reference

2 August 2017

publication date

1 January 2002

1 reference

Trends in Molecular Medicine

2 August 2017

published in

1 reference

2 August 2017

volume

8

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

17-23

1 reference

Signal transduction by receptors with tyrosine kinase activity

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

RTK mutations and human syndromeswhen good receptors turn bad.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

FGF receptor mutations: dimerization syndromes, cell growth suppression, and animal models

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

RET in human development and oncogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

The mutationally activated Met receptor mediates motility and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Co-expression of epidermal growth factor receptor and transforming growth factor-α is independent of ras mutations in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Therapeutic application of anti-growth factor receptor antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

The development of monoclonal antibodies for the therapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Recombinant antibody constructs in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Molecular targets for breast cancer therapy and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Signaling antibodies in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Protein tyrosine kinase inhibitors as novel therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Quick success for cancer kinase treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Development of inhibitors for protein tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Targeting diphtheria toxin to growth factor receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2902217-1

7 January 2021

10.1016/S1471-4914(01)02217-1

Identifiers

DOI

1 reference

2 August 2017

1 reference